首页 > 最新文献

Journal of Research in Pharmacy Practice最新文献

英文 中文
Efficacy of Lacosamide Add-on Therapy on Refractory Focal Epilepsies in Children and Adolescents: An Open-Label Clinical Trial. 拉科沙胺加药治疗儿童和青少年难治性局灶性癫痫的疗效:一项开放标签临床试验。
IF 1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2022-07-01 DOI: 10.4103/jrpp.jrpp_86_21
Tayebeh Mohammadi, Jafar Nasiri, Mohammad Reza Ghazavi, Omid Yaghini, Neda Hoseini

Objective: Epilepsy is a chronic neurological disorder that affects 0.5%-1% of children. 30%-40% of patients are resistant to current anti-epileptic drugs. Lacosamide (LCM) appeared to be effective, safe, and well tolerated in children and adolescents. This study was aimed to evaluate whether LCM could be an effective add-on therapy in children with refractory focal epilepsies.

Methods: This study was conducted from April 2020 to April 2021 in Imam Hossein Children Hospital, Isfahan, Iran. We included 44 children aged 6 months to 16 years with refractory focal epilepsy (based on International League Against Epilepsy criteria). LCM was given in divided doses of 2 mg/kg/day, increasing by 2 mg/kg every week. The first follow-up visit was 6 weeks later, when all patients had reached the therapeutic dose.

Findings: The average age of the patients was 89.9 months. 72.5% of children had focal motor seizures. Evaluation of percent change in seizure frequency and duration before and after treatment showed a 53.22% reduction in seizure frequency and 43.72% reduction in seizure duration after treatment. Our study group tolerated LCM well, with few side effects. Headache, dizziness, and nausea were common side effects. In line with other studies, none of the suspected risk factors could predict response to LCM treatment.

Conclusion: LCM appears to be an effective, safe, and well-tolerated medication in children with uncontrolled drug-resistant focal epilepsy.

目的:癫痫是一种影响0.5%-1%儿童的慢性神经系统疾病。30%-40%的患者对目前的抗癫痫药物有耐药性。拉科沙胺(LCM)在儿童和青少年中似乎是有效、安全且耐受性良好的。本研究旨在评估LCM是否可以作为难治性局灶性癫痫患儿的有效补充治疗。方法:本研究于2020年4月至2021年4月在伊朗伊斯法罕伊玛目侯赛因儿童医院进行。我们纳入了44名6个月至16岁的难治性局灶性癫痫患儿(基于国际抗癫痫联盟的标准)。LCM分次给药,每天2 mg/kg,每周增加2 mg/kg。第一次随访时间为6周后,所有患者均达到治疗剂量。结果:患者平均年龄89.9个月。72.5%的儿童发生局灶性运动癫痫。治疗前后癫痫发作频率和持续时间的百分比变化评估显示,治疗后癫痫发作频率减少53.22%,癫痫发作持续时间减少43.72%。我们的研究组对LCM耐受性良好,几乎没有副作用。头痛、头晕和恶心是常见的副作用。与其他研究一致,没有任何可疑的危险因素可以预测对LCM治疗的反应。结论:LCM似乎是一种有效、安全且耐受性良好的药物,用于治疗无法控制的耐药局灶性癫痫患儿。
{"title":"Efficacy of Lacosamide Add-on Therapy on Refractory Focal Epilepsies in Children and Adolescents: An Open-Label Clinical Trial.","authors":"Tayebeh Mohammadi,&nbsp;Jafar Nasiri,&nbsp;Mohammad Reza Ghazavi,&nbsp;Omid Yaghini,&nbsp;Neda Hoseini","doi":"10.4103/jrpp.jrpp_86_21","DOIUrl":"https://doi.org/10.4103/jrpp.jrpp_86_21","url":null,"abstract":"<p><strong>Objective: </strong>Epilepsy is a chronic neurological disorder that affects 0.5%-1% of children. 30%-40% of patients are resistant to current anti-epileptic drugs. Lacosamide (LCM) appeared to be effective, safe, and well tolerated in children and adolescents. This study was aimed to evaluate whether LCM could be an effective add-on therapy in children with refractory focal epilepsies.</p><p><strong>Methods: </strong>This study was conducted from April 2020 to April 2021 in Imam Hossein Children Hospital, Isfahan, Iran. We included 44 children aged 6 months to 16 years with refractory focal epilepsy (based on International League Against Epilepsy criteria). LCM was given in divided doses of 2 mg/kg/day, increasing by 2 mg/kg every week. The first follow-up visit was 6 weeks later, when all patients had reached the therapeutic dose.</p><p><strong>Findings: </strong>The average age of the patients was 89.9 months. 72.5% of children had focal motor seizures. Evaluation of percent change in seizure frequency and duration before and after treatment showed a 53.22% reduction in seizure frequency and 43.72% reduction in seizure duration after treatment. Our study group tolerated LCM well, with few side effects. Headache, dizziness, and nausea were common side effects. In line with other studies, none of the suspected risk factors could predict response to LCM treatment.</p><p><strong>Conclusion: </strong>LCM appears to be an effective, safe, and well-tolerated medication in children with uncontrolled drug-resistant focal epilepsy.</p>","PeriodicalId":17158,"journal":{"name":"Journal of Research in Pharmacy Practice","volume":"11 3","pages":"109-115"},"PeriodicalIF":1.0,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/fe/ef/JRPP-11-109.PMC10252575.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9611751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of Selenium Supplementation on Lipid Profile, Anemia, and Inflammation Indices in Hemodialysis Patients. 补充硒对血液透析患者血脂、贫血和炎症指标的影响。
IF 1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2022-07-01 DOI: 10.4103/jrpp.jrpp_68_22
Samaneh Assarzadeh, Sahar Vahdat, Shiva Seirafian, Morteza Pourfarzam, Shirinsadat Badri

Objective: Trace elements deficiency is common among end-stage renal disease (ESRD) patients due to excessive loss during dialysis and the lower intake secondary to loss of appetite. Selenium (Se) is a trace element that plays an important role in the radical scavenging system and helps the body defend against oxidative stress. This study aims to evaluate the effects of Se supplementation on lipid profile, anemia, and inflammation indices in ESRD patients.

Methods: Fifty-nine hemodialysis patients enrolled and were randomly divided into two groups. Two hundred microgram Se capsules once daily for the case group and matching placebo for the control group were administered for three months. Demographic data were collected at the study beginning. Uric acid (UA), anemia and inflammation indices, and lipid profiles were recorded at the beginning and the end of the study.

Findings: UA and UA-to-HDL (high-density lipoprotein) ratio decreased significantly in the case group (P < 0.001). The changes in lipid profile were not significant among both groups. Hemoglobin slightly increased in the case group, however, it decreased significantly in the control group (P = 0.031). High-sensitivity C-reactive protein (hs-CRP) decreased in the case group and increased in the control group, however, none of these changes were significant.

Conclusion: According to the results of this study, selenium supplementation in ESRD patients could reduce some risk factors related to their mortality, such as the ratio of uric acid to HDL. However, the changes related to lipid profile, hemoglobin level and hs-CRP biomarker were not significant.

目的:微量元素缺乏在终末期肾病(ESRD)患者中很常见,原因是透析过程中微量元素流失过多,以及继发于食欲不振的微量元素摄入减少。硒(Se)是一种微量元素,在自由基清除系统中起着重要作用,帮助身体抵御氧化应激。本研究旨在评估硒补充对ESRD患者血脂、贫血和炎症指标的影响。方法:59例血液透析患者随机分为两组。病例组每天服用200微克硒胶囊一次,对照组服用相应的安慰剂,持续三个月。在研究开始时收集了人口统计数据。在研究开始和结束时记录尿酸(UA)、贫血和炎症指标以及血脂。结果:病例组UA和UA / hdl(高密度脂蛋白)比值显著降低(P < 0.001)。两组患者血脂变化均不显著。病例组血红蛋白略有升高,对照组血红蛋白明显降低(P = 0.031)。高敏c -反应蛋白(hs-CRP)在病例组中下降,在对照组中升高,但这些变化都不显著。结论:根据本研究结果,ESRD患者补充硒可以降低一些与死亡率相关的危险因素,如尿酸与高密度脂蛋白的比值。然而,血脂、血红蛋白水平和hs-CRP生物标志物的变化不显著。
{"title":"Effect of Selenium Supplementation on Lipid Profile, Anemia, and Inflammation Indices in Hemodialysis Patients.","authors":"Samaneh Assarzadeh,&nbsp;Sahar Vahdat,&nbsp;Shiva Seirafian,&nbsp;Morteza Pourfarzam,&nbsp;Shirinsadat Badri","doi":"10.4103/jrpp.jrpp_68_22","DOIUrl":"https://doi.org/10.4103/jrpp.jrpp_68_22","url":null,"abstract":"<p><strong>Objective: </strong>Trace elements deficiency is common among end-stage renal disease (ESRD) patients due to excessive loss during dialysis and the lower intake secondary to loss of appetite. Selenium (Se) is a trace element that plays an important role in the radical scavenging system and helps the body defend against oxidative stress. This study aims to evaluate the effects of Se supplementation on lipid profile, anemia, and inflammation indices in ESRD patients.</p><p><strong>Methods: </strong>Fifty-nine hemodialysis patients enrolled and were randomly divided into two groups. Two hundred microgram Se capsules once daily for the case group and matching placebo for the control group were administered for three months. Demographic data were collected at the study beginning. Uric acid (UA), anemia and inflammation indices, and lipid profiles were recorded at the beginning and the end of the study.</p><p><strong>Findings: </strong>UA and UA-to-HDL (high-density lipoprotein) ratio decreased significantly in the case group (<i>P</i> < 0.001). The changes in lipid profile were not significant among both groups. Hemoglobin slightly increased in the case group, however, it decreased significantly in the control group (<i>P</i> = 0.031). High-sensitivity C-reactive protein (hs-CRP) decreased in the case group and increased in the control group, however, none of these changes were significant.</p><p><strong>Conclusion: </strong>According to the results of this study, selenium supplementation in ESRD patients could reduce some risk factors related to their mortality, such as the ratio of uric acid to HDL. However, the changes related to lipid profile, hemoglobin level and hs-CRP biomarker were not significant.</p>","PeriodicalId":17158,"journal":{"name":"Journal of Research in Pharmacy Practice","volume":"11 3","pages":"103-108"},"PeriodicalIF":1.0,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f7/e9/JRPP-11-103.PMC10252574.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9617631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Efficacy of an Oral Formulation of Glycyrrhiza glabra, Viola odorata, and Operculina turpethum as an Add-on Therapy for Mild-to-moderate Childhood Asthma: A Randomized Placebo-Controlled Clinical Trial. 甘草、堇菜和甲壳草口服制剂作为轻中度儿童哮喘附加治疗的疗效:一项随机安慰剂对照临床试验。
IF 1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2022-07-01 DOI: 10.4103/jrpp.jrpp_77_22
Faezeh Rabbani, Mohsen Raeisi, Majid Keivanfar, Ali Saffaei, Ali Mohammad Sabzghabaee

Objective: We aimed to evaluate the efficacy of an oral combined tablet of Glycyrrhiza glabra, Viola odorata, and Operculina turpethum (Anti-Asthma®) as an add-on therapy for the relief of the severity of symptoms in mild-to-moderate childhood asthma.

Methods: This randomized placebo-controlled clinical trial was performed on 60 children and adolescents with chronic mild-to-moderate childhood asthma. Patients were randomly divided into cases who received Anti-Asthma® oral combined tablets 2 tablets twice dailt for 1 month and controls, received placebo tablets identically the same to Anti-Asthma® (2 tablets, twice daily, for 1 month) as add-ons to their standard therapy according to the guideline. The severity and frequency of cough attacks and shortness of breath, respiratory test indices (based on spirometry), and the extent of disease control and treatment adherence were measured clinically by validated questionnaires at the beginning and after the study.

Findings: Respiratory test indices improved and the severity of activity restriction decreased significantly in the cases compared to the controls However, the mean difference before and after the study was significantly different between the cases and controls only for the number and severity of coughs and the severity of activity restriction. In the scores of the Asthma Control Questionnaire, the cases group had a significant improvement compared to the controls.

Conclusion: Anti-Asthma® oral formulation may be effective as an adjunct add-on treatment in the maintenance therapy of mild-to-moderate childhood asthma.

目的:我们旨在评估一种口服甘草、堇菜和猪皮草联合片(抗哮喘®)作为缓解轻中度儿童哮喘症状严重程度的附加治疗的疗效。方法:本随机安慰剂对照临床试验对60例慢性轻中度儿童哮喘儿童和青少年进行研究。患者随机分为两组,一组服用抗哮喘®口服联合片剂2片,每日2次,持续1个月;另一组服用与抗哮喘®相同的安慰剂片剂(2片,每日2次,持续1个月),作为标准治疗的补充。在研究开始时和研究结束后,通过有效的问卷临床测量咳嗽发作和呼吸短促的严重程度和频率、呼吸试验指标(基于肺活量测定法)、疾病控制程度和治疗依从性。结果:与对照组相比,病例呼吸试验指标改善,限制活动严重程度明显降低,但仅咳嗽次数和严重程度以及限制活动严重程度与对照组相比,研究前后的平均差异有显著差异。在哮喘控制问卷的得分上,病例组与对照组相比有显著改善。结论:抗哮喘®口服制剂可作为轻中度儿童哮喘维持治疗的辅助治疗手段。
{"title":"The Efficacy of an Oral Formulation of <i>Glycyrrhiza glabra</i>, <i>Viola odorata</i>, and <i>Operculina turpethum</i> as an Add-on Therapy for Mild-to-moderate Childhood Asthma: A Randomized Placebo-Controlled Clinical Trial.","authors":"Faezeh Rabbani,&nbsp;Mohsen Raeisi,&nbsp;Majid Keivanfar,&nbsp;Ali Saffaei,&nbsp;Ali Mohammad Sabzghabaee","doi":"10.4103/jrpp.jrpp_77_22","DOIUrl":"https://doi.org/10.4103/jrpp.jrpp_77_22","url":null,"abstract":"<p><strong>Objective: </strong>We aimed to evaluate the efficacy of an oral combined tablet of <i>Glycyrrhiza glabra, Viola odorata, and Operculina turpethum</i> (Anti-Asthma<sup>®</sup>) as an add-on therapy for the relief of the severity of symptoms in mild-to-moderate childhood asthma.</p><p><strong>Methods: </strong>This randomized placebo-controlled clinical trial was performed on 60 children and adolescents with chronic mild-to-moderate childhood asthma. Patients were randomly divided into cases who received Anti-Asthma<sup>®</sup> oral combined tablets 2 tablets twice dailt for 1 month and controls, received placebo tablets identically the same to Anti-Asthma<sup>®</sup> (2 tablets, twice daily, for 1 month) as add-ons to their standard therapy according to the guideline. The severity and frequency of cough attacks and shortness of breath, respiratory test indices (based on spirometry), and the extent of disease control and treatment adherence were measured clinically by validated questionnaires at the beginning and after the study.</p><p><strong>Findings: </strong>Respiratory test indices improved and the severity of activity restriction decreased significantly in the cases compared to the controls However, the mean difference before and after the study was significantly different between the cases and controls only for the number and severity of coughs and the severity of activity restriction. In the scores of the Asthma Control Questionnaire, the cases group had a significant improvement compared to the controls.</p><p><strong>Conclusion: </strong>Anti-Asthma<sup>®</sup> oral formulation may be effective as an adjunct add-on treatment in the maintenance therapy of mild-to-moderate childhood asthma.</p>","PeriodicalId":17158,"journal":{"name":"Journal of Research in Pharmacy Practice","volume":"11 3","pages":"116-123"},"PeriodicalIF":1.0,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/92/10/JRPP-11-116.PMC10252578.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9617628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Evaluation of the Effectiveness of an Herbal Formulation of Boswellia sacra Flueck. In Improving Cognitive and Behavioral Symptoms in Patients with Cognitive Impairment and Alzheimer's Disease. 乳香草中药制剂的疗效评价。改善认知障碍和阿尔茨海默病患者的认知和行为症状。
IF 1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2022-07-01 DOI: 10.4103/jrpp.jrpp_73_22
Mahsa Panahishokouh, Maryam Noroozian, Fatemeh Mohammadian, Mahnaz Khanavi, Mahnaz Mirimoghaddam, Seyed Mehrdad Savar, Maryam Nikoosokhan, Hooshyar Honarmand, Niayesh Mohebbi

Objective: This study aimed to assess the efficacy of an herbal formulation based on Boswellia sacra in improving cognitive and behavioral symptoms in patients with mild cognitive impairment (MCI) and mild-to-moderate stages of Alzheimer's disease (AD).

Methods: A 3-month, parallel-group, placebo-controlled trial was implemented from October 2021 to April 2022. Patients with MCI and mild-to-moderate stages of AD aged above 50 years (n = 60; 40 women, 20 men) enrolled in the study using clinical diagnosis and a score of 10-30 on the mini-mental state examination (MMSE) test. They were assigned into two groups; one receiving a herbal formulation) include B. sacra, Melissa officinalis, Piper longum, Cinnamomum verum, and Physalis alkekengi) three times a day and the other receiving a placebo for 3 months. The main efficacy measures were the changes in cognitive domains based on the MMSE and changes in behavioral and psychiatric symptoms based on neuropsychiatric inventory (NPI) scores compared with baseline. Side effects were also recorded.

Findings: Results of this study showed significant differences between the two groups after 3 months in terms of all the assessed variables, including the overall result of the mean score of MMSE and NPI tests (P ≤ 0.001). The herbal formulation had the most considerable effects on the domains of orientation, attention, working memory, delay recall, and language of the MMSE test.

Conclusion: Herbal formulation based on B. sacra was significantly effective compared to a placebo in improving cognitive and behavioral symptoms in patients with MCI and mild-to-moderate AD.

目的:本研究旨在评估以乳香草为基础的中药制剂对轻度认知障碍(MCI)和轻中度阿尔茨海默病(AD)患者认知和行为症状的改善效果。方法:从2021年10月至2022年4月进行为期3个月的平行组安慰剂对照试验。年龄在50岁以上的轻度认知障碍和轻中度AD患者(n = 60;40名女性,20名男性)通过临床诊断和10-30分的迷你精神状态检查(MMSE)测试加入了这项研究。他们被分成两组;一组每天服用三次草药制剂(包括骶骨B., Melissa officinalis, Piper longum, Cinnamomum verum和Physalis alkekengi),另一组服用安慰剂,持续3个月。主要疗效测量是基于MMSE的认知领域的变化,以及基于神经精神量表(NPI)评分的行为和精神症状与基线相比的变化。同时也记录了副作用。结果:本研究结果显示,两组在3个月后的所有评估变量,包括MMSE和NPI测试平均得分的总体结果,均有显著差异(P≤0.001)。中药配方对MMSE测试的定向、注意、工作记忆、延迟回忆和语言等领域的影响最为显著。结论:与安慰剂相比,以骶骨为基础的草药制剂在改善轻度认知损伤和轻度至中度AD患者的认知和行为症状方面显着有效。
{"title":"Evaluation of the Effectiveness of an Herbal Formulation of <i>Boswellia sacra Flueck</i>. In Improving Cognitive and Behavioral Symptoms in Patients with Cognitive Impairment and Alzheimer's Disease.","authors":"Mahsa Panahishokouh,&nbsp;Maryam Noroozian,&nbsp;Fatemeh Mohammadian,&nbsp;Mahnaz Khanavi,&nbsp;Mahnaz Mirimoghaddam,&nbsp;Seyed Mehrdad Savar,&nbsp;Maryam Nikoosokhan,&nbsp;Hooshyar Honarmand,&nbsp;Niayesh Mohebbi","doi":"10.4103/jrpp.jrpp_73_22","DOIUrl":"https://doi.org/10.4103/jrpp.jrpp_73_22","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to assess the efficacy of an herbal formulation based on <i>Boswellia sacra</i> in improving cognitive and behavioral symptoms in patients with mild cognitive impairment (MCI) and mild-to-moderate stages of Alzheimer's disease (AD).</p><p><strong>Methods: </strong>A 3-month, parallel-group, placebo-controlled trial was implemented from October 2021 to April 2022. Patients with MCI and mild-to-moderate stages of AD aged above 50 years (<i>n</i> = 60; 40 women, 20 men) enrolled in the study using clinical diagnosis and a score of 10-30 on the mini-mental state examination (MMSE) test. They were assigned into two groups; one receiving a herbal formulation) include <i>B. sacra, Melissa officinalis, Piper longum, Cinnamomum verum, and Physalis alkekengi</i>) three times a day and the other receiving a placebo for 3 months. The main efficacy measures were the changes in cognitive domains based on the MMSE and changes in behavioral and psychiatric symptoms based on neuropsychiatric inventory (NPI) scores compared with baseline. Side effects were also recorded.</p><p><strong>Findings: </strong>Results of this study showed significant differences between the two groups after 3 months in terms of all the assessed variables, including the overall result of the mean score of MMSE and NPI tests (<i>P</i> ≤ 0.001). The herbal formulation had the most considerable effects on the domains of orientation, attention, working memory, delay recall, and language of the MMSE test.</p><p><strong>Conclusion: </strong>Herbal formulation based on <i>B. sacra</i> was significantly effective compared to a placebo in improving cognitive and behavioral symptoms in patients with MCI and mild-to-moderate AD.</p>","PeriodicalId":17158,"journal":{"name":"Journal of Research in Pharmacy Practice","volume":"11 3","pages":"91-98"},"PeriodicalIF":1.0,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/16/1c/JRPP-11-91.PMC10252576.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9619488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Adverse Drug Reactions in Psychiatry Outpatient Department of a Tertiary Care Hospital in Western Uttar Pradesh: An Observational Study. 西北方邦某三级医院精神科门诊药物不良反应:一项观察性研究。
IF 1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2022-07-01 DOI: 10.4103/jrpp.jrpp_51_22
Jaspreet Kaur Sidhu, Kiran Jakhar, Deepti Chopra, Aditi Dhote, Vishakha Babber, Mohammad Shadman, C D Tripathi

Objective: Psychiatric disorders are chronic in nature which require medications for a long duration. These medications have been associated with many adverse events. Failure to recognize an adverse drug reaction (ADR) exposes the patient to continuing risk of ADR, leading to a significant impact on patient's quality of life. Thus, the present study carried out to identify the pattern of ADRs reported due to psychotropic medication.

Methods: This was a cross-sectional study conducted to analyze ADRs reported from the psychiatry department of a tertiary care teaching hospital from October 2021 to March 2022.

Findings: A total of 137 ADRs were identified from 102 patients. Majority of the ADRs were reported from antidepressants, with paroxetine being the leading offending drug. The central nervous system was most commonly affected, and dizziness (13.13%) was the most common ADR noted. On causality assessment, 97 ADRs (70.8%) were of "possible" type. Almost half of the patients with ADRs (47.5%) recovered spontaneously. No ADR encountered turned out to be fatal.

Conclusion: The present study revealed that the majority of ADRs reported from psychiatry OPD were mild in nature. We reinforce the identification of ADR is crucial in the hospital setting process as it gives an insight into the risk-benefit ratio for rational use of the drug.

目的:精神疾病是慢性的,需要长期的药物治疗。这些药物与许多不良事件有关。未能识别药物不良反应(ADR)会使患者面临持续的ADR风险,从而对患者的生活质量产生重大影响。因此,本研究旨在确定精神药物引起的不良反应报告的模式。方法:这是一项横断面研究,分析2021年10月至2022年3月一家三级护理教学医院精神科报告的不良反应。结果:102例患者共发现137例不良反应。据报道,大多数不良反应来自抗抑郁药,帕罗西汀是主要的致病药物。最常见的不良反应是中枢神经系统,头晕(13.13%)是最常见的不良反应。在因果关系评价中,97例adr为“可能”型,占70.8%。几乎一半的不良反应患者(47.5%)自发恢复。没有出现致命的不良反应。结论:本研究显示精神科门诊报告的大多数不良反应是轻微的。我们强调,在医院设置过程中,ADR的识别是至关重要的,因为它提供了对合理使用药物的风险-收益比的洞察。
{"title":"Adverse Drug Reactions in Psychiatry Outpatient Department of a Tertiary Care Hospital in Western Uttar Pradesh: An Observational Study.","authors":"Jaspreet Kaur Sidhu,&nbsp;Kiran Jakhar,&nbsp;Deepti Chopra,&nbsp;Aditi Dhote,&nbsp;Vishakha Babber,&nbsp;Mohammad Shadman,&nbsp;C D Tripathi","doi":"10.4103/jrpp.jrpp_51_22","DOIUrl":"https://doi.org/10.4103/jrpp.jrpp_51_22","url":null,"abstract":"<p><strong>Objective: </strong>Psychiatric disorders are chronic in nature which require medications for a long duration. These medications have been associated with many adverse events. Failure to recognize an adverse drug reaction (ADR) exposes the patient to continuing risk of ADR, leading to a significant impact on patient's quality of life. Thus, the present study carried out to identify the pattern of ADRs reported due to psychotropic medication.</p><p><strong>Methods: </strong>This was a cross-sectional study conducted to analyze ADRs reported from the psychiatry department of a tertiary care teaching hospital from October 2021 to March 2022.</p><p><strong>Findings: </strong>A total of 137 ADRs were identified from 102 patients. Majority of the ADRs were reported from antidepressants, with paroxetine being the leading offending drug. The central nervous system was most commonly affected, and dizziness (13.13%) was the most common ADR noted. On causality assessment, 97 ADRs (70.8%) were of \"possible\" type. Almost half of the patients with ADRs (47.5%) recovered spontaneously. No ADR encountered turned out to be fatal.</p><p><strong>Conclusion: </strong>The present study revealed that the majority of ADRs reported from psychiatry OPD were mild in nature. We reinforce the identification of ADR is crucial in the hospital setting process as it gives an insight into the risk-benefit ratio for rational use of the drug.</p>","PeriodicalId":17158,"journal":{"name":"Journal of Research in Pharmacy Practice","volume":"11 3","pages":"99-102"},"PeriodicalIF":1.0,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/9e/41/JRPP-11-99.PMC10252573.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9619489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association Between Atorvastatin Exposure and Low Folate Status: A Case-Control Study. 阿托伐他汀暴露与低叶酸状态之间的关系:一项病例对照研究。
IF 1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2022-07-01 DOI: 10.4103/jrpp.jrpp_66_22
Roberto Lozano, Irati Apesteguía, Alejandro Martínez

Objective: The objective of this study is to assess the association between exposure to atorvastatin (ATV) and low-plasma folate (PF) status.

Methods: The sample consisted of patients admitted to the internal medicine service of a basic general hospital, located in Zaragoza (Spain). We adopted a pharmacoepidemiological case-control study design. For this, the number of treatment days (TDs) of all the drugs part of their treatment during the study period was obtained from each patient in the sample. The cases were comprised by the number of patient's TDs for which PF ≤3 mg/dl and the controls by the number of patient's TDs for which PF >3 mg/dl. To measure the strength of the association, the odds ratios (ORs) were calculated. The Chi-square test, using the Bonferroni correction, was used to calculate the statistical significance.

Findings: The sample consisted of 640 polymedicated patients. The mean PF obtained were 8.0 ± 4.6 mg/dl and 2.1 ± 0.6 mg/dl, for the cases and controls, respectively; the total number of TDs for the cases and controls were 7615 and 57899, respectively. We obtained a U-shaped curve when representing the dose of ATV against the corresponding ORs when comparing cases with control.

Conclusion: Exposure to ATV at 10 or 80 mg is associated with an augmented risk of low folate status. We recommend implementing guidelines for mandatory folic acid fortification in patients exposed to ATV doses of 10 or 80 mg.

目的:本研究的目的是评估暴露于阿托伐他汀(ATV)和低血浆叶酸(PF)状态之间的关系。方法:以西班牙萨拉戈萨市某基础综合医院内科收治的患者为样本。我们采用药物流行病学病例对照研究设计。为此,从样本中每个患者获得研究期间所有药物部分治疗的治疗天数(TDs)。以PF≤3mg /dl的TDs数为例,以PF > 3mg /dl的TDs数为对照组。为了衡量这种关联的强度,我们计算了比值比(ORs)。采用卡方检验,采用Bonferroni校正,计算统计学显著性。结果:样本包括640例多药患者。患者和对照组的平均PF值分别为8.0±4.6 mg/dl和2.1±0.6 mg/dl;病例和对照组总td数分别为7615和57899。当将病例与对照进行比较时,我们得到了一条u形曲线,表示亚硝酸钠的剂量与相应的ORs。结论:暴露于10或80毫克的ATV与低叶酸状态的风险增加有关。我们建议对暴露于ATV剂量为10或80毫克的患者实施强制性叶酸强化指南。
{"title":"Association Between Atorvastatin Exposure and Low Folate Status: A Case-Control Study.","authors":"Roberto Lozano,&nbsp;Irati Apesteguía,&nbsp;Alejandro Martínez","doi":"10.4103/jrpp.jrpp_66_22","DOIUrl":"https://doi.org/10.4103/jrpp.jrpp_66_22","url":null,"abstract":"<p><strong>Objective: </strong>The objective of this study is to assess the association between exposure to atorvastatin (ATV) and low-plasma folate (PF) status.</p><p><strong>Methods: </strong>The sample consisted of patients admitted to the internal medicine service of a basic general hospital, located in Zaragoza (Spain). We adopted a pharmacoepidemiological case-control study design. For this, the number of treatment days (TDs) of all the drugs part of their treatment during the study period was obtained from each patient in the sample. The cases were comprised by the number of patient's TDs for which PF ≤3 mg/dl and the controls by the number of patient's TDs for which PF >3 mg/dl. To measure the strength of the association, the odds ratios (ORs) were calculated. The Chi-square test, using the Bonferroni correction, was used to calculate the statistical significance.</p><p><strong>Findings: </strong>The sample consisted of 640 polymedicated patients. The mean PF obtained were 8.0 ± 4.6 mg/dl and 2.1 ± 0.6 mg/dl, for the cases and controls, respectively; the total number of TDs for the cases and controls were 7615 and 57899, respectively. We obtained a U-shaped curve when representing the dose of ATV against the corresponding ORs when comparing cases with control.</p><p><strong>Conclusion: </strong>Exposure to ATV at 10 or 80 mg is associated with an augmented risk of low folate status. We recommend implementing guidelines for mandatory folic acid fortification in patients exposed to ATV doses of 10 or 80 mg.</p>","PeriodicalId":17158,"journal":{"name":"Journal of Research in Pharmacy Practice","volume":"11 3","pages":"124-126"},"PeriodicalIF":1.0,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/16/9d/JRPP-11-124.PMC10252577.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9623251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Potential Benefits of Selenium Supplementation in Patients with Kidney Disease. 补充硒对肾病患者的潜在益处
IF 1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2022-05-25 eCollection Date: 2021-10-01 DOI: 10.4103/jrpp.jrpp_3_22
Shirinsadat Badri, Sahar Vahdat, Morteza Pourfarzam, Samaneh Assarzadeh, Shiva Seirafian, Sara Ataei

Trace element deficiency is common among patients with end-stage renal disease (ESRD); the reason is that since these patients undergo dialysis, they lose these elements more than healthy people, and also the use of trace elements is restricted due to loss of appetite. Selenium (Se) is a trace element that is essential for the oxidative stress defense system. Se deficiency leads to some complications similar to those often seen in ESRD patients, such as all-cause mortality due to cardiovascular diseases, bone loss, uric acid elevation, and anemia. This article aims to review the evidence on consequences of Se deficiency in ESRD patients, as well as effects of Se supplementation in hemodialysis patients. Multiple databases were searched to summarize the available evidence on selenium's role in kidney diseases. Since the complications of ESRD and those of Se deficiency are mostly similar, this triggers the idea that Se deficiency may be considered as a cause of these problems, but it needs to be more assessed that Se deficiency is a single factor or there are other factors participated in. Also the role of Se supplementation on resolving the mentioned complications, needs to be more studied through welldesigned clinical studies.

微量元素缺乏在终末期肾病(ESRD)患者中很常见;原因是由于这些患者接受透析治疗,他们比健康人更容易失去这些元素,而且由于食欲不振,微量元素的使用也受到限制。硒(Se)是一种对氧化应激防御系统至关重要的微量元素。硒缺乏导致一些与ESRD患者相似的并发症,如心血管疾病、骨质流失、尿酸升高和贫血引起的全因死亡率。本文旨在回顾ESRD患者硒缺乏后果的证据,以及补充硒对血液透析患者的影响。我们检索了多个数据库,总结了硒在肾脏疾病中的作用的现有证据。由于ESRD的并发症与硒缺乏的并发症大多相似,这引发了硒缺乏可能被认为是这些问题的原因的想法,但需要更多地评估硒缺乏是单一因素还是有其他因素参与。硒补充对上述并发症的解决作用,需要通过精心设计的临床研究来进一步研究。
{"title":"Potential Benefits of Selenium Supplementation in Patients with Kidney Disease.","authors":"Shirinsadat Badri,&nbsp;Sahar Vahdat,&nbsp;Morteza Pourfarzam,&nbsp;Samaneh Assarzadeh,&nbsp;Shiva Seirafian,&nbsp;Sara Ataei","doi":"10.4103/jrpp.jrpp_3_22","DOIUrl":"https://doi.org/10.4103/jrpp.jrpp_3_22","url":null,"abstract":"<p><p>Trace element deficiency is common among patients with end-stage renal disease (ESRD); the reason is that since these patients undergo dialysis, they lose these elements more than healthy people, and also the use of trace elements is restricted due to loss of appetite. Selenium (Se) is a trace element that is essential for the oxidative stress defense system. Se deficiency leads to some complications similar to those often seen in ESRD patients, such as all-cause mortality due to cardiovascular diseases, bone loss, uric acid elevation, and anemia. This article aims to review the evidence on consequences of Se deficiency in ESRD patients, as well as effects of Se supplementation in hemodialysis patients. Multiple databases were searched to summarize the available evidence on selenium's role in kidney diseases. Since the complications of ESRD and those of Se deficiency are mostly similar, this triggers the idea that Se deficiency may be considered as a cause of these problems, but it needs to be more assessed that Se deficiency is a single factor or there are other factors participated in. Also the role of Se supplementation on resolving the mentioned complications, needs to be more studied through welldesigned clinical studies.</p>","PeriodicalId":17158,"journal":{"name":"Journal of Research in Pharmacy Practice","volume":"10 4","pages":"149-158"},"PeriodicalIF":1.0,"publicationDate":"2022-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/56/5f/JRPP-10-149.PMC9235365.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40406028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of the Effectiveness of N-Acetylcysteine in the Prevention of Colistin-Induced Nephrotoxicity: A Randomized Controlled Clinical Trial. 评价n-乙酰半胱氨酸预防粘菌素所致肾毒性的有效性:一项随机对照临床试验。
IF 1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2022-05-25 eCollection Date: 2021-10-01 DOI: 10.4103/jrpp.jrpp_90_21
Sedigheh Mosayebi, Rasool Soltani, Fatemeh Shafiee, Samane Assarzadeh, Atousa Hakamifard

Objective: The present study aimed to evaluate the effectiveness of N-Acetylcysteine (NAC), as an antioxidant, in preventing nephrotoxicity in patients receiving colistin.

Methods: In a randomized controlled clinical trial, eligible participants receiving colistin were divided into two groups including drug (n = 43) and control (n = 39). In the drug group, 1200 mg of NAC was administered daily for 10 days concurrently with colistin. Patients in the control group received only colistin. The serum creatinine level (SCr), blood urea nitrogen (BUN), and creatinine clearance (CrCl) at baseline and every other day, and the number of cases with acute kidney injury (AKI) during the study were recorded. Before starting treatment and on day 5, the level of urinary neutrophil gelatinase-associated lipocalin (NGAL) was determined. Finally, the values were compared between the groups.

Findings: There was a significant increase in SCr and BUN and a significant reduction in CrCl in both groups, but there was not any significant difference between the two groups at any time. Changes in the urine NGAL levels were not significantly different between the two groups. Even though the number of cases with AKI in the drug group (8 cases, 18.6%) was less than the control group (11 cases, 28.2%), the difference was not statistically significant (P = 0.303).

Conclusion: Simultaneous administration of NAC with a dose of 1200 mg daily does not have any effect in the prevention of colistin-induced nephrotoxicity.

目的:本研究旨在评价n -乙酰半胱氨酸(NAC)作为抗氧化剂预防多粘菌素患者肾毒性的有效性。方法:采用随机对照临床试验,将符合条件的接受粘菌素治疗的受试者分为药物组(n = 43)和对照组(n = 39)。药物组每日给予NAC 1200mg,连续10天,同时给予粘菌素。对照组患者仅给予粘菌素治疗。记录两组患者基线及隔日血清肌酐水平(SCr)、血尿素氮(BUN)、肌酐清除率(CrCl)及研究期间急性肾损伤(AKI)病例数。在开始治疗前和第5天,测定尿中性粒细胞明胶酶相关脂钙蛋白(NGAL)水平。最后比较两组间的数值。结果:两组患者SCr、BUN均显著升高,CrCl均显著降低,但两组间任何时间均无显著差异。两组间尿NGAL水平变化无显著差异。药物组AKI发生率(8例,18.6%)虽低于对照组(11例,28.2%),但差异无统计学意义(P = 0.303)。结论:每日1200mg同时给药NAC对预防粘菌素所致肾毒性无明显作用。
{"title":"Evaluation of the Effectiveness of N-Acetylcysteine in the Prevention of Colistin-Induced Nephrotoxicity: A Randomized Controlled Clinical Trial.","authors":"Sedigheh Mosayebi,&nbsp;Rasool Soltani,&nbsp;Fatemeh Shafiee,&nbsp;Samane Assarzadeh,&nbsp;Atousa Hakamifard","doi":"10.4103/jrpp.jrpp_90_21","DOIUrl":"https://doi.org/10.4103/jrpp.jrpp_90_21","url":null,"abstract":"<p><strong>Objective: </strong>The present study aimed to evaluate the effectiveness of N-Acetylcysteine (NAC), as an antioxidant, in preventing nephrotoxicity in patients receiving colistin.</p><p><strong>Methods: </strong>In a randomized controlled clinical trial, eligible participants receiving colistin were divided into two groups including drug (<i>n</i> = 43) and control (<i>n</i> = 39). In the drug group, 1200 mg of NAC was administered daily for 10 days concurrently with colistin. Patients in the control group received only colistin. The serum creatinine level (SCr), blood urea nitrogen (BUN), and creatinine clearance (CrCl) at baseline and every other day, and the number of cases with acute kidney injury (AKI) during the study were recorded. Before starting treatment and on day 5, the level of urinary neutrophil gelatinase-associated lipocalin (NGAL) was determined. Finally, the values were compared between the groups.</p><p><strong>Findings: </strong>There was a significant increase in SCr and BUN and a significant reduction in CrCl in both groups, but there was not any significant difference between the two groups at any time. Changes in the urine NGAL levels were not significantly different between the two groups. Even though the number of cases with AKI in the drug group (8 cases, 18.6%) was less than the control group (11 cases, 28.2%), the difference was not statistically significant (<i>P</i> = 0.303).</p><p><strong>Conclusion: </strong>Simultaneous administration of NAC with a dose of 1200 mg daily does not have any effect in the prevention of colistin-induced nephrotoxicity.</p>","PeriodicalId":17158,"journal":{"name":"Journal of Research in Pharmacy Practice","volume":"10 4","pages":"159-165"},"PeriodicalIF":1.0,"publicationDate":"2022-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/33/df/JRPP-10-159.PMC9235367.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40409998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Comparative Evaluation between the LaxaPlus Barij® and Polyethylene Glycol (4000) in the Pediatric Functional Constipation in Children 2-15 Years Old. LaxaPlus Barij®与聚乙二醇(4000)治疗2-15岁儿童功能性便秘的比较评价
IF 1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2022-05-25 eCollection Date: 2021-10-01 DOI: 10.4103/jrpp.jrpp_57_21
Peiman Nasri, Shima Saeidi, Hosein Saneian, Fatemeh Famouri, Somayeh Sadeghi, Leila Mohammad Taghizadeh Kashani, Majid Khademian

Objective: This study aimed to compare the LaxaPlus Barij® and polyethylene glycol (4000) in pediatric (children 2-15 years old) functional constipation.

Methods: The present study is a randomized clinical trial. The study population included patients with functional constipation aged 2-15 years who were referred to the gastrointestinal clinic of Imam Hossein hospital in Isfahan in 2019. Patients were randomly assigned into two treatment groups. Data analysis was performed using SPSS software. The significance level in the present study is considered <0.05.

Findings: Sixty children with functional constipation were selected based on the inclusion and exclusion criteria in this study. The present study results showed no significant difference between demographic characteristics, including age, weight, and gender of children with constipation in the two groups (P > 0.05). The present study results showed that both groups' mean stool consistency and the number of bowel movements increased significantly after the intervention (P < 0.05). However, the number of bowel movements in the first group was significantly higher than in the second group (P < 0.05).

Conclusion: The present study results showed that both drugs effectively treat children with functional constipation. However, after 8 weeks of intervention, the frequency of bowel movements, pain intensity, and abdominal pain in the group LaxaPlus Barij® was more effective. However, the level of satisfaction did not differ significantly between the two groups.

目的:本研究旨在比较LaxaPlus Barij®和聚乙二醇(4000)在儿童(2-15岁)功能性便秘中的作用。方法:本研究为随机临床试验。研究人群包括2019年转诊至伊斯法罕伊玛目侯赛因医院胃肠门诊的2-15岁功能性便秘患者。患者被随机分为两个治疗组。采用SPSS软件进行数据分析。结果:根据本研究的纳入和排除标准,选择60例功能性便秘患儿。本研究结果显示,两组便秘患儿的年龄、体重、性别等人口学特征差异无统计学意义(P > 0.05)。本研究结果显示,干预后两组平均大便稠度和排便次数均显著增加(P < 0.05)。但第一组的排便次数明显高于第二组(P < 0.05)。结论:本研究结果表明,两种药物均能有效治疗儿童功能性便秘。然而,干预8周后,LaxaPlus Barij®组的排便频率、疼痛强度和腹痛更有效。然而,满意度在两组之间没有显著差异。
{"title":"Comparative Evaluation between the LaxaPlus Barij<sup>®</sup> and Polyethylene Glycol (4000) in the Pediatric Functional Constipation in Children 2-15 Years Old.","authors":"Peiman Nasri,&nbsp;Shima Saeidi,&nbsp;Hosein Saneian,&nbsp;Fatemeh Famouri,&nbsp;Somayeh Sadeghi,&nbsp;Leila Mohammad Taghizadeh Kashani,&nbsp;Majid Khademian","doi":"10.4103/jrpp.jrpp_57_21","DOIUrl":"https://doi.org/10.4103/jrpp.jrpp_57_21","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to compare the LaxaPlus Barij<sup>®</sup> and polyethylene glycol (4000) in pediatric (children 2-15 years old) functional constipation.</p><p><strong>Methods: </strong>The present study is a randomized clinical trial. The study population included patients with functional constipation aged 2-15 years who were referred to the gastrointestinal clinic of Imam Hossein hospital in Isfahan in 2019. Patients were randomly assigned into two treatment groups. Data analysis was performed using SPSS software. The significance level in the present study is considered <0.05.</p><p><strong>Findings: </strong>Sixty children with functional constipation were selected based on the inclusion and exclusion criteria in this study. The present study results showed no significant difference between demographic characteristics, including age, weight, and gender of children with constipation in the two groups (<i>P</i> > 0.05). The present study results showed that both groups' mean stool consistency and the number of bowel movements increased significantly after the intervention (<i>P</i> < 0.05). However, the number of bowel movements in the first group was significantly higher than in the second group (<i>P</i> < 0.05).</p><p><strong>Conclusion: </strong>The present study results showed that both drugs effectively treat children with functional constipation. However, after 8 weeks of intervention, the frequency of bowel movements, pain intensity, and abdominal pain in the group LaxaPlus Barij<sup>®</sup> was more effective. However, the level of satisfaction did not differ significantly between the two groups.</p>","PeriodicalId":17158,"journal":{"name":"Journal of Research in Pharmacy Practice","volume":"10 4","pages":"180-184"},"PeriodicalIF":1.0,"publicationDate":"2022-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/5f/cd/JRPP-10-180.PMC9235366.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40409997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Health-Care Professionals' Knowledge and Practice Regarding Disposal of Medicines in Primary Health-Care Facilities in South Africa: Impact and Implications. 卫生保健专业人员在南非初级卫生保健设施处置药品方面的知识和实践:影响和影响。
IF 1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2022-05-25 eCollection Date: 2021-10-01 DOI: 10.4103/jrpp.jrpp_84_21
Kesentseng Jackson Mahlaba, Elvera Anna Helberg, Brian Godman, Amanj Kurdi, Johanna Catharina Meyer

Objective: Professional nurses, pharmacists, and medical practitioners are responsible for disposing of medicines within health-care facilities. South African regulations stipulate that medicines should not be disposed of through sewage systems because of the potential impact on patients and the environment. Consequently, our objective was to determine knowledge and practices among health-care professionals (HCPs) in South Africa and the information they provide to patients regarding the safe disposal of unused/expired/damaged medicines to provide future guidance with identified concerns.

Methods: A descriptive study was conducted among 165 HCPs at 16 primary health-care clinics in two subdistricts of the city of Tshwane in Gauteng Province through self-administered questionnaires.

Findings: Only 23.5% of HCPs stated that they participated in destroying medicines within their facilities. More than half (65.1%) also reported that they always counsel patients regarding the safe storage of their medicines in their homes, with 27.9% indicating they counsel patients on the safe disposal of their medicines during consultations. More than half (65.1%) also reported that patients never asked about the disposal of medicines. Of concern is that incineration (31.9%), flushing down the toilet (20.6%), and flushing down the sink (9.9%) were regarded by HCPs as correct disposal methods, while 9.6% stated that they did not know the correct methods. In addition, 71.1% reported never receiving training regarding the safe disposal of medicine.

Conclusion: There is an urgent need to educate HCPs regarding appropriate medicine waste disposal in South Africa. This can start with including this topic in the curriculum of HCPs, including pharmacists, and continuing post qualification.

目的:专业护士、药剂师和医疗从业人员负责处理卫生保健设施内的药物。南非法规规定,由于对患者和环境的潜在影响,药品不应通过污水系统处理。因此,我们的目标是确定南非卫生保健专业人员(HCPs)的知识和做法,以及他们向患者提供的关于安全处置未使用/过期/损坏药物的信息,以便为确定的问题提供未来指导。方法:通过问卷调查,对豪登省茨瓦内市两个街道16家初级卫生保健诊所的165名卫生保健专业人员进行描述性研究。调查结果:只有23.5%的医务人员表示他们参与销毁其设施内的药品。超过一半(65.1%)的受访者还报告说,他们总是就在家中安全储存药品向患者提供咨询,27.9%的受访者表示,他们在咨询期间就安全处置药品向患者提供咨询。超过一半(65.1%)的医生还报告说,患者从未询问过药物的处置。值得关注的是,医务人员认为焚烧(31.9%)、冲厕(20.6%)和冲水槽(9.9%)是正确的处置方法,而9.6%的人表示不知道正确的处置方法。此外,71.1%报告从未接受过有关安全处置药品的培训。结论:南非迫切需要对医务人员进行适当的医疗废物处理教育。这可以从将这一主题纳入HCPs(包括药剂师)的课程和继续岗位资格开始。
{"title":"Health-Care Professionals' Knowledge and Practice Regarding Disposal of Medicines in Primary Health-Care Facilities in South Africa: Impact and Implications.","authors":"Kesentseng Jackson Mahlaba,&nbsp;Elvera Anna Helberg,&nbsp;Brian Godman,&nbsp;Amanj Kurdi,&nbsp;Johanna Catharina Meyer","doi":"10.4103/jrpp.jrpp_84_21","DOIUrl":"https://doi.org/10.4103/jrpp.jrpp_84_21","url":null,"abstract":"<p><strong>Objective: </strong>Professional nurses, pharmacists, and medical practitioners are responsible for disposing of medicines within health-care facilities. South African regulations stipulate that medicines should not be disposed of through sewage systems because of the potential impact on patients and the environment. Consequently, our objective was to determine knowledge and practices among health-care professionals (HCPs) in South Africa and the information they provide to patients regarding the safe disposal of unused/expired/damaged medicines to provide future guidance with identified concerns.</p><p><strong>Methods: </strong>A descriptive study was conducted among 165 HCPs at 16 primary health-care clinics in two subdistricts of the city of Tshwane in Gauteng Province through self-administered questionnaires.</p><p><strong>Findings: </strong>Only 23.5% of HCPs stated that they participated in destroying medicines within their facilities. More than half (65.1%) also reported that they always counsel patients regarding the safe storage of their medicines in their homes, with 27.9% indicating they counsel patients on the safe disposal of their medicines during consultations. More than half (65.1%) also reported that patients never asked about the disposal of medicines. Of concern is that incineration (31.9%), flushing down the toilet (20.6%), and flushing down the sink (9.9%) were regarded by HCPs as correct disposal methods, while 9.6% stated that they did not know the correct methods. In addition, 71.1% reported never receiving training regarding the safe disposal of medicine.</p><p><strong>Conclusion: </strong>There is an urgent need to educate HCPs regarding appropriate medicine waste disposal in South Africa. This can start with including this topic in the curriculum of HCPs, including pharmacists, and continuing post qualification.</p>","PeriodicalId":17158,"journal":{"name":"Journal of Research in Pharmacy Practice","volume":"10 4","pages":"185-190"},"PeriodicalIF":1.0,"publicationDate":"2022-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/71/6e/JRPP-10-185.PMC9235368.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40406030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
期刊
Journal of Research in Pharmacy Practice
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1